Rutin: A Potential Antiviral for Repurposing as a SARS-CoV-2 Main Protease (M <sup>pro</sup> ) Inhibitor
Pawan K. Agrawal, Chandan Agrawal, Gerald Blunden
Abstract
Various computational studies, including in silico ones, have identified several existing compounds that could serve as effective inhibitors of the SARS-CoV-2 main protease (M pro ), and thus preventing replication of the virus. Among these, rutin has been identified as a potential hit, having prominent binding affinity to the virus. Moreover, its presence in several traditional antiviral medicines prescribed in China to infected patients with mild to moderate symptoms of COVID-19 justify its promise as a repurposed bioactive secondary metabolite against SARS-CoV-2.
Topics & Concepts
RutinRepurposingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ProteaseVirologyIn silicoCoronavirus disease 2019 (COVID-19)VirusDrug repositioningViral replicationProtease inhibitor (pharmacology)2019-20 coronavirus outbreakChemistryMetabolitePharmacologyCoronavirusBiologyEnzymeMedicineBiochemistryViral loadDrugPathologyAntiretroviral therapyGeneDiseaseInfectious disease (medical specialty)AntioxidantEcologyOutbreakComputational Drug Discovery MethodsPhytochemicals and Medicinal PlantsAndrographolide Research and Applications